YTD
As of 30/11/2024
10.44%
Fund size
As of 03/01/2025
USD 3.88 Bn
Risk indicator
The risk indicator assumes you keep the product for 5 year(s). See Key Information Document (KID) for details.
1
2
3
4
5
6
7
Lower risk
Higher risk
Fund facts
SEDOLBKWBX23
ISINLU1048171810
BloombergJPGHDAE LX
ReutersLU1048171810.LUF
Asset classEquity
RegionGlobal
Fund currencyUSD
Share class currencyEUR
Fund inception date02/10/2009
Share class inception26/03/2014
ESG Approach ESG Promote
SFDR Classification Article 8
Fund stats
Fund size
As of 03/01/2025USD 3.88 Bn
As of 03/01/2025USD 3.88 Bn
Investment objective
To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.
Key risks
The Sub-Fund is subject to Investment risks and Other associated risks from the techniques and securities it uses to seek to achieve its objective. The table below explains how these risks relate to each other and the Outcomes to the Shareholder that could affect an investment in the Sub-Fund.
Investors should also read Risk Descriptions in the Prospectus for a full description of each risk.
Investment risks
Risks from the Sub-Fund’s techniques and securities
Techniques
Concentration
Hedging
Securities
Equities
Smaller companies
Other associated risks
Further risks the Sub-Fund is exposed to from its use of the techniques and securities above
Currency
Liquidity
Market
Outcomes to the Shareholder
Potential impact of the risks above
Loss
Shareholders could lose some or all of their money.
Volatility
Shares of the Sub-Fund will fluctuate in value.
Failure to meet the Sub-Fund's objective
Portfolio managers
27 YEARS
In the industry
5 YEARS
With J.P. Morgan
2 YEARS
Managing this fund
29 YEARS
In the industry
7 YEARS
With J.P. Morgan
Less than one year
Managing this fund
Registered countries
Austria
27/10/2017
Belgium
04/12/2017
Finland
18/01/2018
France
19/06/2014
Germany
27/11/2014
Greece
02/05/2022
Ireland
26/05/2015
Italy
20/11/2015
Jersey
27/03/2014
Korea
01/02/2017
Liechtenstein
31/07/2015
Luxembourg
27/03/2014
Netherlands
27/03/2014
Portugal
17/03/2021
Spain
31/03/2014
Sweden
18/01/2018
Switzerland
27/03/2014
United Kingdom
26/05/2015
"-" = Registered, but date of registration not known
Risk indicator
The risk indicator assumes you keep the product for 5 year(s). See Key Information Document (KID) for details.
1
2
3
4
5
6
7
Lower risk
Higher risk
Fund facts
SEDOLBKWBX23
ISINLU1048171810
BloombergJPGHDAE LX
ReutersLU1048171810.LUF
Asset classEquity
RegionGlobal
Fund currencyUSD
Share class currencyEUR
Fund inception date02/10/2009
Share class inception26/03/2014
ESG Approach ESG Promote
SFDR Classification Article 8
Fund stats
Fund size
As of 03/01/2025USD 3.88 Bn
As of 03/01/2025USD 3.88 Bn
Performance
Benchmark
MSCI World Healthcare Index (Total Return Net)
Performance - Cumulative
1 MONTH | 3 MONTHS | 1 YEAR | 3 YEARS | 5 YEARS | 10 YEARS | |
---|---|---|---|---|---|---|
JPM C (acc) - EUR | 1.90% | -4.98% | 17.05% | 14.24% | 49.01% | 117.82% |
Benchmark | 1.89% | -4.07% | 16.16% | 20.92% | 55.15% | 148.59% |
Excess return (geometric) | 0.01% | -0.94% | 0.76% | -5.53% | -3.96% | -12.38% |
Performance - ANNUALIZED
3 YEARS | 5 YEARS | 10 YEARS | |
---|---|---|---|
JPM C (acc) - EUR | 4.54% | 8.30% | 8.10% |
Benchmark | 6.54% | 9.18% | 9.53% |
Excess return (geometric) | -1.88% | -0.80% | -1.31% |
Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees.
Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.
The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation.
Indices do not include fees or operating expenses and you cannot invest in them.
The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.
Fees
Initial charge
0.00%
Redemption charge
0.00%
Ongoing charge (comprises)
1.00%
Annual management fee
0.80%
Operating & administrative expenses
0.20%
ESG Introduction
Please review our policies, disclosures and ESG reports to help inform your investment decisions.
Find out more about our approach, and read our latest sustainable investing insights.
Find out more about our approach, and read our latest sustainable investing insights.
ESG Approach
ESG Promote
Promotes environmental and / or social characteristics.
SFDR Classification
Article 8
DOCUMENTS
This is a marketing communication and as such the views contained herein do not form part of an offer, nor are they to be taken as advice or a recommendation, to buy or sell any investment or interest thereto. Reliance upon information in this material is at the sole discretion of the reader. Any research in this document has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are, unless otherwise stated, J.P. Morgan Asset Management’s own at the date of this document. They are considered to be reliable at the time of writing, may not necessarily be all inclusive and are not guaranteed as to accuracy. They may be subject to change without reference or notification to you. It should be noted that the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Changes in exchange rates may have an adverse effect on the value, price or income of the products or underlying overseas investments. Past performance and yield are not a reliable indicator of current and future results. There is no guarantee that any forecast made will come to pass. Furthermore, whilst it is the intention to achieve the investment objective of the investment products, there can be no assurance that those objectives will be met. J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide. To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy.
As the product may not be authorised or its offering may be restricted in your jurisdiction, it is the responsibility of every reader to satisfy himself as to the full observance of the laws and regulations of the relevant jurisdiction. Prior to any application investors are advised to take all necessary legal, regulatory and tax advice on the consequences of an investment in the products. Shares or other interests may not be offered to, or purchased, directly or indirectly by US persons. All transactions should be based on the latest available Prospectus, the Key Information Document (KID) and any applicable local offering document. These documents together with the annual report, semi-annual report, the articles of incorporation and sustainability-related disclosures for the Luxembourg domiciled products are available in English free of charge upon request from JPMorgan Asset Management (Europe) S.à r.l., 6 route de Trèves, L-2633 Senningerberg, Grand Duchy of Luxembourg, your financial adviser, your J.P. Morgan Asset Management regional contact or at https://am.jpmorgan.com. A summary of investor rights is available in English at https://am.jpmorgan.com/lu/investor-rights.
This communication is issued in Europe (excluding UK) by JPMorgan Asset Management (Europe) S.à r.l., 6 route de Trèves, L-2633 Senningerberg, Grand Duchy of Luxembourg, R.C.S. Luxembourg B27900, corporate capital EUR 10.000.000.
As the product may not be authorised or its offering may be restricted in your jurisdiction, it is the responsibility of every reader to satisfy himself as to the full observance of the laws and regulations of the relevant jurisdiction. Prior to any application investors are advised to take all necessary legal, regulatory and tax advice on the consequences of an investment in the products. Shares or other interests may not be offered to, or purchased, directly or indirectly by US persons. All transactions should be based on the latest available Prospectus, the Key Information Document (KID) and any applicable local offering document. These documents together with the annual report, semi-annual report, the articles of incorporation and sustainability-related disclosures for the Luxembourg domiciled products are available in English free of charge upon request from JPMorgan Asset Management (Europe) S.à r.l., 6 route de Trèves, L-2633 Senningerberg, Grand Duchy of Luxembourg, your financial adviser, your J.P. Morgan Asset Management regional contact or at https://am.jpmorgan.com. A summary of investor rights is available in English at https://am.jpmorgan.com/lu/investor-rights.
This communication is issued in Europe (excluding UK) by JPMorgan Asset Management (Europe) S.à r.l., 6 route de Trèves, L-2633 Senningerberg, Grand Duchy of Luxembourg, R.C.S. Luxembourg B27900, corporate capital EUR 10.000.000.